699 related articles for article (PubMed ID: 33017150)
1. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
Aikins ME; Xu C; Moon JJ
Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
[TBL] [Abstract][Full Text] [Related]
2. Synthetic Particles for Cancer Vaccines: Connecting the Inherent Supply Chain.
Xia Y; Song T; Hu Y; Ma G
Acc Chem Res; 2020 Oct; 53(10):2068-2080. PubMed ID: 32945648
[TBL] [Abstract][Full Text] [Related]
3. Cancer Vaccines Designed Based the Nanoparticle and Tumor Cells for the Treatment of Tumors: A Perspective.
Wu QJ; Lv WL
IET Nanobiotechnol; 2024; 2024():5593879. PubMed ID: 38863969
[TBL] [Abstract][Full Text] [Related]
4. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
Ni K; Luo T; Nash GT; Lin W
Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle delivery systems in cancer vaccines.
Krishnamachari Y; Geary SM; Lemke CD; Salem AK
Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
[TBL] [Abstract][Full Text] [Related]
6. Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.
Li S; Bennett ZT; Sumer BD; Gao J
Acc Chem Res; 2020 Nov; 53(11):2546-2557. PubMed ID: 33063517
[TBL] [Abstract][Full Text] [Related]
7. Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance.
Xu Z; Zhou H; Li T; Yi Q; Thakur A; Zhang K; Ma X; Qin JJ; Yan Y
Drug Resist Updat; 2024 Jul; 75():101098. PubMed ID: 38833804
[TBL] [Abstract][Full Text] [Related]
8. Lymph node-targeting nanovaccines for cancer immunotherapy.
Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle-mediated tumor vaccines for personalized therapy: preparing tumor antigens
Li Q; Li J; Song S; Chen W; Shen X; Li S; Xing D
J Mater Chem B; 2021 Mar; 9(10):2352-2366. PubMed ID: 33659970
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle-based immunotherapy for cancer.
Shao K; Singha S; Clemente-Casares X; Tsai S; Yang Y; Santamaria P
ACS Nano; 2015 Jan; 9(1):16-30. PubMed ID: 25469470
[TBL] [Abstract][Full Text] [Related]
11. Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy.
Nguyen TL; Choi Y; Kim J
Adv Mater; 2019 Aug; 31(34):e1803953. PubMed ID: 30417454
[TBL] [Abstract][Full Text] [Related]
12. Nanovaccines with cell-derived components for cancer immunotherapy.
Meng Z; Zhang Y; Zhou X; Ji J; Liu Z
Adv Drug Deliv Rev; 2022 Mar; 182():114107. PubMed ID: 34995678
[TBL] [Abstract][Full Text] [Related]
13. Nanomedicines for an Enhanced Immunogenic Cell Death-Based
Zhao C; Wang C; Shan W; Wang Z; Chen X; Deng H
Acc Chem Res; 2024 Mar; 57(6):905-918. PubMed ID: 38417027
[TBL] [Abstract][Full Text] [Related]
14. Vaccine-like nanomedicine for cancer immunotherapy.
Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
[TBL] [Abstract][Full Text] [Related]
15. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
[No Abstract] [Full Text] [Related]
16. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen.
Cole G; Ali AA; McErlean E; Mulholland EJ; Short A; McCrudden CM; McCaffrey J; Robson T; Kett VL; Coulter JA; Dunne NJ; Donnelly RF; McCarthy HO
Acta Biomater; 2019 Sep; 96():480-490. PubMed ID: 31299353
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle mediated cancer immunotherapy.
Gupta J; Safdari HA; Hoque M
Semin Cancer Biol; 2021 Feb; 69():307-324. PubMed ID: 32259643
[TBL] [Abstract][Full Text] [Related]
19. Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.
Chiozzini C; Olivetta E; Sanchez M; Arenaccio C; Ferrantelli F; Leone P; Federico M
J Mol Med (Berl); 2019 Aug; 97(8):1139-1153. PubMed ID: 31161312
[TBL] [Abstract][Full Text] [Related]
20. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response.
Yu X; Dai Y; Zhao Y; Qi S; Liu L; Lu L; Luo Q; Zhang Z
Nat Commun; 2020 Feb; 11(1):1110. PubMed ID: 32111828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
